Login
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc.

larimartx.com

What Do They Do?

Develops nomlabofusp, a protein therapy intended to deliver frataxin to cells, for people with Friedreich’s ataxia, and uses its cell-penetrating peptide platform to pursue treatments for other rare diseases.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +35% (Loss)
vs −$47.7M in Q3 FY2025
  • Nov 9, 2026 Completed rolling BLA submission for nomlabofusp The application seeks accelerated approval to treat patients with Friedreich’s ataxia.
  • Jun 29, 2026 Submitted first BLA module and reported open-label study data The filing seeks accelerated approval of nomlabofusp for Friedreich’s ataxia.

Who Do They Compete With?

Competes with Biogen, Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Solid Biosciences, and PTC Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support